Bennett Levitan

2.0k total citations
80 papers, 1.3k citations indexed

About

Bennett Levitan is a scholar working on Economics and Econometrics, Cardiology and Cardiovascular Medicine and Pharmacology. According to data from OpenAlex, Bennett Levitan has authored 80 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Economics and Econometrics, 18 papers in Cardiology and Cardiovascular Medicine and 18 papers in Pharmacology. Recurrent topics in Bennett Levitan's work include Health Systems, Economic Evaluations, Quality of Life (34 papers), Pharmaceutical industry and healthcare (18 papers) and Atrial Fibrillation Management and Outcomes (16 papers). Bennett Levitan is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (34 papers), Pharmaceutical industry and healthcare (18 papers) and Atrial Fibrillation Management and Outcomes (16 papers). Bennett Levitan collaborates with scholars based in United States, United Kingdom and Netherlands. Bennett Levitan's co-authors include Esther W. de Bekker‐Grob, Juhaeri Juhaeri, Chiara Whichello, Jorien Veldwijk, Isabelle Huys, Žhong Yuan, Eline van Overbeeke, Brett Hauber, Stuart Kauffman and Cathy Anne Pinto and has published in prestigious journals such as Circulation, Blood and Journal of the American College of Cardiology.

In The Last Decade

Bennett Levitan

79 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Bennett Levitan United States 20 530 265 158 152 119 80 1.3k
Hwanhee Hong United States 24 131 0.2× 68 0.3× 303 1.9× 98 0.6× 56 0.5× 103 2.8k
Jeanne Lenzer United States 16 284 0.5× 261 1.0× 59 0.4× 19 0.1× 235 2.0× 166 1.3k
Gregory W. Daniel United States 20 343 0.6× 90 0.3× 213 1.3× 13 0.1× 32 0.3× 46 1.5k
Jeppe Bennekou Schroll Denmark 16 331 0.6× 143 0.5× 109 0.7× 12 0.1× 434 3.6× 38 1.7k
Suja S. Rajan United States 21 117 0.2× 232 0.9× 49 0.3× 122 0.8× 17 0.1× 84 1.6k
Emily R. Cox Australia 20 610 1.2× 183 0.7× 88 0.6× 9 0.1× 159 1.3× 56 1.5k
Mir S. Siadaty United States 21 125 0.2× 365 1.4× 330 2.1× 127 0.8× 12 0.1× 34 2.3k
Alun Bedding United Kingdom 16 184 0.3× 41 0.2× 151 1.0× 25 0.2× 52 0.4× 32 1.3k
Pascale Tubert‐Bitter France 22 122 0.2× 55 0.2× 102 0.6× 27 0.2× 39 0.3× 70 1.8k
Margaret Haugh France 18 141 0.3× 157 0.6× 243 1.5× 85 0.6× 11 0.1× 35 1.3k

Countries citing papers authored by Bennett Levitan

Since Specialization
Citations

This map shows the geographic impact of Bennett Levitan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bennett Levitan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bennett Levitan more than expected).

Fields of papers citing papers by Bennett Levitan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bennett Levitan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bennett Levitan. The network helps show where Bennett Levitan may publish in the future.

Co-authorship network of co-authors of Bennett Levitan

This figure shows the co-authorship network connecting the top 25 collaborators of Bennett Levitan. A scholar is included among the top collaborators of Bennett Levitan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bennett Levitan. Bennett Levitan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yuan, Žhong, Bennett Levitan, Hsiaowei Deng, et al.. (2024). Quantitative Benefit–Risk Evaluation of Rivaroxaban in Patients After Peripheral Arterial Revascularization: The VOYAGER PAD Trial. Journal of the American Heart Association. 13(8). e032782–e032782. 3 indexed citations
2.
Tervonen, Tommi, et al.. (2023). Treatment preferences in relation to fatigue of patients with relapsing multiple sclerosis: A discrete choice experiment. Multiple Sclerosis Journal - Experimental Translational and Clinical. 9(1). 3090513570–3090513570. 4 indexed citations
3.
Pinto, Cathy Anne, Tommi Tervonen, Cecilia Jimenez‐Moreno, et al.. (2023). Current Practices and Challenges When Submitting Patient Experience Data for Regulatory Decisions by the US Food and Drug Administration: An Industry Survey. Patient. 17(2). 147–159. 4 indexed citations
4.
Levitan, Bennett, Stephen C. Hadler, William Hurst, et al.. (2023). The Brighton collaboration standardized module for vaccine benefit-risk assessment. Vaccine. 42(4). 972–986. 5 indexed citations
5.
Lackey, Leila G., Jorien Veldwijk, Praveen Thokala, et al.. (2023). Illustrating Emerging Good Practices for Quantitative Benefit-Risk Assessment: A Hypothetical Case Study of Systemic Biologic Treatments for Plaque Psoriasis. Value in Health. 26(4). 519–527. 4 indexed citations
6.
Fox, Robert J., Tommi Tervonen, Anne Brooks, et al.. (2022). The relevance of fatigue to relapse rate in multiple sclerosis: Applying patient preference data to the OPTIMUM trial. Multiple Sclerosis Journal. 29(3). 427–435. 2 indexed citations
7.
Raskob, Gary E., Walter Ageno, Gregory W. Albers, et al.. (2022). Benefit–Risk Assessment of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness. Journal of the American Heart Association. 11(20). e026229–e026229. 7 indexed citations
8.
Spyropoulos, Alex C., Concetta Lipardi, Eunyoung Suh, et al.. (2019). Improved Benefit Risk Profile of Rivaroxaban in a Subpopulation of the MAGELLAN Study. Clinical and Applied Thrombosis/Hemostasis. 25. 2873284550–2873284550. 46 indexed citations
9.
Raskob, Gary E., Alex C. Spyropoulos, Alexander T. Cohen, et al.. (2019). Abstract 12863: Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness: Pooled Analysis of Mortality and Major Thromboembolic Events in 16,496 Patients From the MAGELLAN and MARINER Trials. Circulation. 3 indexed citations
10.
Gibson, C. Michael, Bennett Levitan, William J. Gibson, et al.. (2018). Fatal or Irreversible Bleeding and Ischemic Events With Rivaroxaban in Acute Coronary Syndrome. Journal of the American College of Cardiology. 72(2). 129–136. 12 indexed citations
11.
Soekhai, Vikas, Chiara Whichello, Bennett Levitan, et al.. (2017). Compendium Of Methods For Measuring Patient Preferences In Medical Treatment. Value in Health. 20(9). A684–A685. 6 indexed citations
12.
Ho, Martin, Anindita Saha, Kimberly McCleary, et al.. (2016). A Framework for Incorporating Patient Preferences Regarding Benefits and Risks into Regulatory Assessment of Medical Technologies. Value in Health. 19(6). 746–750. 100 indexed citations
13.
Katz, Eva G., Brett Hauber, Srihari Gopal, et al.. (2016). Physician and patient benefit–risk preferences from two randomized long-acting injectable antipsychotic trials. Patient Preference and Adherence. Volume 10. 2127–2139. 21 indexed citations
14.
Whalley, D, Brett Hauber, Joshua Posner, et al.. (2015). Patients’ Priorities For Treatment In Severe Asthma. Value in Health. 18(7). A504–A504. 1 indexed citations
15.
Markowitz, Michael A., Dong‐Jing Fu, Bennett Levitan, et al.. (2013). Long-acting injectable paliperidone palmitate versus oral paliperidone extended release: a comparative analysis from two placebo-controlled relapse prevention studies. Annals of General Psychiatry. 12(1). 22–22. 28 indexed citations
16.
17.
Levitan, Bennett, Žhong Yuan, Juan Marcos González, et al.. (2013). Patient And Physician Preferences In The United States For Benefits And Risks Of Anticoagulant Use In Atrial Fibrillation – Results From A Conjoint-Analysis Study. Value in Health. 16(3). A11–A11. 3 indexed citations
18.
González, Juan Marcos, Brett Hauber, Bennett Levitan, & Paul Coplan. (2012). PND36 Structured Benefit-Risk Assessment of Triptan Treatments Using Patient-Preference Data. Value in Health. 15(4). A147–A147. 1 indexed citations
19.
Okumura, Kazuhiro, Hiroshi Inoue, Masahiro Yasaka, et al.. (2012). PCV101 Japanese Patients and Physicians Preferences for Anticoagulants Use in Atrial Fibrillation - Results From a Conjoint-Analysis Study. Value in Health. 15(7). A380–A380. 3 indexed citations
20.
Levitan, Bennett & Stuart Kauffman. (1995). Adaptive walks with noisy fitness measurements. Molecular Diversity. 1(1). 53–68. 41 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hwanhee Hong Breakdown of academic impact, for papers by Jeanne Lenzer Breakdown of academic impact, for papers by Gregory W. Daniel Breakdown of academic impact, for papers by Jeppe Bennekou Schroll Breakdown of academic impact, for papers by Suja S. Rajan Breakdown of academic impact, for papers by Emily R. Cox Breakdown of academic impact, for papers by Mir S. Siadaty Breakdown of academic impact, for papers by Alun Bedding Breakdown of academic impact, for papers by Pascale Tubert‐Bitter Breakdown of academic impact, for papers by Margaret Haugh
Rankless by CCL
2026